Groundshot: a pan-European, patient-centred, and data-driven approach to tackling cancer
Cet article met en avant les enjeux liés à la recherche sur le cancer en Europe
In 2017, inspired by the US Cancer Moonshot initiative, The Lancet Oncology published a Commission on cancer research priorities in the USA. Writing in a Comment reflecting on this Commission from a European perspective, Fortunato Ciardiello and Josep Tabernero remarked, “as scientists and doctors working in Europe, we…believe that The Lancet Oncology Commission presents research priorities that must also be discussed within the European Union (EU)...[because]…large disparities in national cancer research programmes and actions in cancer care still exist between EU countries.” This astute observation has become even more complicated in the intervening years because of the UK's exit from the EU (Brexit), the COVID-19 pandemic, the Russian invasion of Ukraine, the cost-of-living crisis, and the impending risk of a global recession. In 2018, Bishal Gyawali and colleagues noted that, “although the high-tech science that is supported by the Cancer Moonshot initiative might set new standards and programmes to benefit some patients…a parallel cancer groundshot is needed to improve the lives of patients with cancer today and in the next two decades. This strategy would focus on the implementation of treatments that are already known to work, incentivising research on affordable and cost-effective interventions for cancer control.” Today, we publish a new Commission that aims to address these issues: European Groundshot—addressing Europe's cancer research challenges.
The Lancet Oncology 2022